Copyright © 2025 Authors retain the copyright of this article. This article is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

@article{185219,
        author = {Siddhika Raut and Pranita Rikame and Ankita Rathod and Priya Daingade and Tushar shelke},
        title = {Dosimetry in radionuclide therapy its challanges and innovation},
        journal = {International Journal of Innovative Research in Technology},
        year = {2025},
        volume = {12},
        number = {5},
        pages = {364-375},
        issn = {2349-6002},
        url = {https://ijirt.org/article?manuscript=185219},
        abstract = {Systemically administered radiopharmaceuticals are used in radionuclide therapy (RNT), a rapidly expanding cancer treatment technique, to target and kill cancer cells.  Although the amount of absorbed radiation supplied to target tissues directly affects the effectiveness and toxicity of RNT, clinical practice has traditionally relied on fixed or empirical dosing regimens. Optimising the therapeutic dose while minimising harm to healthy organs at risk (OAR) is one way that moving towards personalised, dosimetry-guided treatment promises to improve patient outcomes.  This review addresses the development of RNT dosimetry, emphasising significant obstacles as well as new developments in imaging, computer techniques, and radiobiological modelling that are opening the door for its broader clinical application.},
        keywords = {Dosimetry Radionuclide Therapy Absorbed Dose SPECT /CT Maximum targeted activity (MTA)},
        month = {October},
        }